{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for azelaic root_modifications_structuralModifications_molecularFragment_refPname in root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Elcatonin is a physio-chemically stable calcitonin derivative in which the disulfide bond between cysteine residues at positions 1 and 7 of eel calcitonin has been replaced by an ethylene bond. The primary pharmacological effect of Elcatonin is its activity at specific osteoclast receptors, resulting in diminished osteoclast activity at extremely low concentrations. Elcatonin inhibits the bones autolysis and renal calcium, phosphorus, and sodium reabsorption thus keeps blood calcium at a normal level. In clinical settings, once-weekly intramuscular injection of elcatonin has been shown to significantly increase bone mineral density within 6 months and to alleviate post-fracture pain and improve Quality of life in osteoporosis
Status:
Possibly Marketed Outside US
Source:
NCT00370877: Phase 4 Interventional Completed Postpartum Hemorrhage
(2007)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT01981083: Phase 4 Interventional Unknown status Protein-Energy Malnutrition
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:azoximer bromide [INN]
Source URL:
Class:
POLYMER
Status:
Other
Class:
POLYMER
Status:
Other
Class:
POLYMER
Status:
Other
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NDA020884
(1999)
Source URL:
First approved in 1999
Source:
NDA020884
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NDA050795
(1967)
Source URL:
First approved in 1967
Source:
NDA050795
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
INN:enadenotucirev [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE